NCT04065217

Brief Summary

In an academic, government clinic, uni-center, randomized within patients trial study of the effects of 980-nm diode laser treatment included 15 cases of facial hemangiomas in patients with a history of discomfort due to lesions that were not suitable for removal using traditional methods. The study was carried out at the University of Baghdad/Institute of Laser for Postgraduate Studies/Laser Medicine Research Clinics from 15 October 2018 to 15 April 2019. Primary end-point is improvement of conditions at 6 months. Secondary end-points are quality of life, disappear lesions and safety administration of diode laser. Each patient received 12 sessions at two-week intervals. Lesions were photographed before and after laser treatment and digital image histograms were generated as a graphical representation of the tonal distribution. Following treatment, the lesions were less elevated, smoother in texture, and the color changed from dark red to light pink. There is a need to improve the treatment of face hemangiomas. Results from this randomized within patient trial will serve as preliminary evidence of the future role of diode laser in hemangioma treatment and a basis for design and power estimations of future studies. Based on the skin texture, color and elevation of the hemangioma as well as patient satisfaction, this type of laser is a safe and effective modality for the treatment of facial hemangioma in Iraqi patients.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
15

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Oct 2018

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 14, 2018

Completed
10 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 30, 2019

Completed
16 days until next milestone

Study Completion

Last participant's last visit for all outcomes

August 15, 2019

Completed
1 day until next milestone

First Submitted

Initial submission to the registry

August 16, 2019

Completed
6 days until next milestone

First Posted

Study publicly available on registry

August 22, 2019

Completed
Last Updated

August 22, 2019

Status Verified

August 1, 2019

Enrollment Period

10 months

First QC Date

August 16, 2019

Last Update Submit

August 20, 2019

Conditions

Keywords

HemangiomaRandomized within patientDiode laserHistogram

Outcome Measures

Primary Outcomes (3)

  • Area of Hemangioma lesions

    Measured area of lesions by tape measure by centimeters

    4th week

  • Color of lesion

    By inspection color of lesion change from dark red to bright red or disappear

    4 weeks

  • Shape of lesion

    Clinical exam by inspection, we look to ugly shape of lesion, may be change for better or disappear

    4 weeks

Study Arms (1)

Iraqi patients with face hemangioma

OTHER

Diode laser 980-nm in the diseased group only while we no need the comparator group because we compared between lesion before and after. The administration of laser is scheduled to start treatment. Patients will take laser therapy as a 12 session at two week-interval. In case of intolerance, session number reduction by 10, 8, 6, 4 allowed. Adherence to treatment will be assessed at each interval for undesired side effects or complications. The intervention should continue also after complete session, or during temporary interval withdrawal due to reached maximal cumulative response or side effects from laser therapy.

Procedure: Diode laser 980-nm

Interventions

Before starting the laser session, cosmetics or makeup were removed and the skin was cleaned. The area was anesthetized by the application of as EMLA lotion (lidocaine 2.5% + prilocaine 2.5%) \[ONLY MEDICAL; CAT No. R331/72394/P001\] 20 minutes before the session. During the procedure, the laser probe was held perpendicular to the lesion and a guide beam was used to direct the application. The patient wore protective eye goggles \[CE; DIR 8001100L4\]. After the session, cool air was applied to the whole region. Each patient received a maximum of six sessions, delivered at two-week intervals. Patients reported itchiness and erythema during the session.

Iraqi patients with face hemangioma

Eligibility Criteria

Age5 Years - 60 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64)

You may qualify if:

  • Comfortable.
  • Superficial lesion.

You may not qualify if:

  • Advanced case.
  • Deep lesion.
  • Uncomfortable.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Institute of Laser for Postgraduate Studies

Baghdad, 10001, Iraq

Location

MeSH Terms

Conditions

Hemangioma

Interventions

Lasers, Semiconductor

Condition Hierarchy (Ancestors)

Neoplasms, Vascular TissueNeoplasms by Histologic TypeNeoplasms

Intervention Hierarchy (Ancestors)

LasersOptical DevicesEquipment and SuppliesRadiation Equipment and Supplies

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Model Details: uni-center, government clinic, randomized within patient trial
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Assistant Lecturer

Study Record Dates

First Submitted

August 16, 2019

First Posted

August 22, 2019

Study Start

October 14, 2018

Primary Completion

July 30, 2019

Study Completion

August 15, 2019

Last Updated

August 22, 2019

Record last verified: 2019-08

Data Sharing

IPD Sharing
Will share

Data availability

Shared Documents
STUDY PROTOCOL, SAP, CSR
Time Frame
one year
Access Criteria
Open
More information

Locations